Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Lipidomics of hormone-sensitive lipase variants (Study ST000662)

C18 NEGATIVE ION MODE (Analysis AN001010)

Metabolite	Structure	F1	F2	F3
CL 68:0; [M-2H](2-)@7.59	ME177780	0.34	5.92	0.26
plasmenyl-PE 36:0; [M-H]-@8.07	ME178005	0.27	6.07	0.28
plasmenyl-PE 35:0; [M-H]-@7.74	ME178004	0.59	4.22	0.51
CL 68:2; [M-2H](2-)@7.29	ME177781	0.52	4.63	0.45
PE 38:1; [M-H]-@7.83	ME177907	0.39	4.90	0.48
PE 38:2; [M-H]-@7.40	ME177908	0.40	4.83	0.49
plasmenyl-PE 38:1; [M-H]-@8.10	ME178013	0.52	3.68	0.69
PC 36:6; [M-Ac-H]-@5.38	ME177843	0.69	3.37	0.64
PE 37:1; [M-H]-@7.56	ME177901	0.75	3.46	0.58
plasmenyl-PE 38:2; [M-H]-@7.70	ME178014	0.66	3.49	0.63
plasmenyl-PE 36:1; [M-H]-@7.63	ME178006	0.71	3.02	0.71
PE 40:2; [M-H]-@7.92	ME177920	0.54	3.20	0.79
PI 34:2; [M-H]-@5.24	ME177956	0.43	3.21	0.88
PE 36:4; [M-H]-@5.79	ME177897	0.97	2.44	0.66
PE 36:0; [M-H]-@7.09	ME177887	0.63	2.62	0.87
plasmenyl-PE 40:4; [M-H]-@7.64	ME178022	0.58	2.63	0.91
PE 40:4; [M-H]-@7.32	ME177922	0.63	2.33	0.94
PI 36:3; [M-H]-@5.42	ME177959	0.70	2.35	0.88
PE 36:0; [M-H]-@7.75	ME177888	0.74	2.55	0.80
PE 36:1; [M-H]-@7.34	ME177889	0.74	2.45	0.83
PC 37:5; [M-Ac-H]-@6.35	ME177847	0.30	2.11	1.25
PE 40:3; [M-H]-@6.99	ME177921	0.62	1.76	1.10
PI 36:1; [M-H]-@6.29	ME177957	0.57	1.93	1.09
PE 39:1; [M-H]-@8.09	ME177917	0.79	2.19	0.86
PI 36:2; [M-H]-@5.82	ME177958	0.57	2.16	1.03
plasmenyl-PE 42:4; [M-H]-@7.99	ME178026	0.58	2.15	1.02
PC 42:5; [M-Ac-H]-@7.32	ME177866	1.65	0.67	0.59
PC 44:4; [M-Ac-H]-@8.35	ME177867	2.05	0.32	0.39
PS 38:4; [M-H]-@5.99	ME177975	0.28	0.18	1.75
PS 40:6; [M-H]-@5.83	ME177980	0.31	0.12	1.74
PS 42:10; [M-H]-@4.80	ME177982	0.34	0.26	1.68
PS 38:3; [M-H]-@6.19	ME177974	0.38	0.20	1.66
PS 40:5; [M-H]-@6.05	ME177979	0.40	0.24	1.64
PS 40:7; [M-H]-@5.38	ME177981	0.39	0.38	1.61
PI 34:1; [M-H]-@5.69	ME177955	0.36	0.56	1.59
PS 40:4; [M-H]-@6.39	ME177978	0.31	0.50	1.64
plasmenyl-PE 40:3; [M-H]-@7.96	ME178021	0.82	NA	1.12
lysoPE 22:5; [M-H]-@1.45	ME177995	0.85	0.26	1.30
PS 38:6; [M-H]-@5.23	ME177977	0.90	0.17	1.28
PE 42:10; [M-H]-@5.79	ME177930	0.53	0.26	1.54
PS 36:2; [M-H]-@5.92	ME177970	0.61	0.34	1.46
PC 40:1; [M-Ac-H]-@8.30	ME177858	0.75	0.42	1.33
PE 40:8; [M-H]-@5.85	ME177929	0.77	0.44	1.31
lysoPE 22:4; [M-H]-@1.78	ME177994	0.71	0.49	1.35
PG 36:1; [M-H]-@6.43	ME177938	0.69	0.50	1.36
PC 40:6; [M-Ac-H]-@6.58	ME177861	0.75	0.56	1.29
PE 40:7; [M-H]-@6.29	ME177928	0.72	0.50	1.27
PS 36:1; [M-H]-@6.40	ME177969	0.49	0.73	1.45
PG 37:4; [M-H]-@6.37	ME177943	0.49	0.53	1.50
PS 34:1; [M-H]-@5.86	ME177967	0.60	0.52	1.42
PS 38:5; [M-H]-@5.47	ME177976	0.55	0.56	1.44
lysoPE 20:2; [M-H]-@2.00	ME177990	1.30	1.96	0.54
PE 37:3; [M-H]-@6.80	ME177903	0.85	1.79	0.91
PC 35:5; [M-Ac-H]-@5.43	ME177837	0.95	1.88	0.81
plasmenyl-PE 40:2; [M-H]-@8.17	ME178020	0.92	1.87	0.84
plasmenyl-PE 38:3; [M-H]-@7.44	ME178015	1.02	2.00	0.74
MGDG 34:1; [M-H]-@7.05	ME177806	1.17	1.83	0.66
PE 35:0; [M-H]-@7.45	ME177882	1.05	1.85	0.75
plasmenyl-PE 42:6; [M-H]-@7.65	ME178028	1.06	1.85	0.74
plasmenyl-PE 40:1; [M-H]-@8.53	ME178019	1.23	1.34	0.74
CL 76:2; [M-2H](2-)@7.61	ME177789	1.08	1.60	0.79
PC 38:1; [M-Ac-H]-@7.74	ME177849	1.10	1.60	0.77
CL 72:2; [M-2H](2-)@7.47	ME177784	1.14	1.54	0.76
PE 40:1; [M-H]-@8.33	ME177919	1.12	1.48	0.79
PC 37:2; [M-Ac-H]-@6.91	ME177844	1.05	1.35	0.88
plasmenyl-PE 36:2; [M-H]-@7.18	ME178009	1.06	1.46	0.84
PG 36:5; [M-H]-@6.92	ME177942	1.00	1.48	0.88
plasmenyl-PE 36:1; [M-H]-@6.93	ME178007	1.00	1.47	0.89
PG 40:6; [M-H]-@5.24	ME177952	0.62	1.34	1.20
PC 38:2; [M-Ac-H]-@7.33	ME177850	0.68	1.55	1.10
PE 37:2; [M-H]-@6.23	ME177902	0.72	1.51	1.08
PE 38:1; [M-H]-@7.21	ME177906	0.77	1.65	1.01
plasmenyl-PE 42:5; [M-H]-@7.78	ME178027	0.72	1.64	1.05
PI 36:4; [M-H]-@5.20	ME177960	0.89	1.52	0.95
PC 42:10; [M-Ac-H]-@5.65	ME177864	0.80	1.53	1.02
PE 32:0; [M-H]-@6.64	ME177869	0.84	1.52	0.99
plasmenyl-PE 40:5; [M-H]-@7.30	ME178024	0.77	1.43	1.07
PE 38:3; [M-H]-@7.14	ME177910	0.88	1.37	1.00
PC 32:0; [M-Ac-H]-@6.52	ME177821	0.86	1.39	1.01
PI 40:5; [M-H]-@5.94	ME177964	0.85	1.40	1.01
PC 42:2; [M-Ac-H]-@8.44	ME177865	1.37	0.32	0.89
CL 70:3; [M-2H](2-)@5.49	ME177783	1.30	0.33	0.94
lysoPE 20:5; [M-H]-@1.08	ME177993	1.28	0.33	0.96
PC 36:5; [M-Ac-H]-@5.61	ME177842	1.29	0.41	0.93
CL 76:7; [M-2H](2-)@5.91	ME177793	1.27	0.43	0.94
PE 36:3; [M-H]-@5.74	ME177895	1.25	0.43	0.96
CL 72:5; [M-2H](2-)@5.73	ME177785	1.24	0.11	1.04
lysoPE 16:1; [M-H]-@1.15	ME177984	1.19	0.21	1.05
PE 35:3; [M-H]-@5.94	ME177885	1.24	0.27	1.00
PG 32:1; [M-H]-@5.19	ME177931	1.10	0.32	1.09
plasmenyl-PE 33:0; [M-H]-@7.16	ME177998	1.08	0.36	1.10
PE 34:2; [M-H]-@5.26	ME177879	1.08	0.45	1.08
PE 36:2; [M-H]-@5.53	ME177892	1.04	0.44	1.11
PG 34:2; [M-H]-@5.25	ME177933	1.05	0.40	1.11
PC 37:6; [M-Ac-H]-@5.85	ME177848	1.21	0.52	0.96
PE 38:4; [M-H]-@6.18	ME177914	1.26	0.63	0.90
PE 37:1; [M-H]-@6.59	ME177900	1.21	0.63	0.94
CL 78:7; [M-2H](2-)@5.96	ME177796	1.19	0.61	0.96
lysoPE 18:2; [M-H]-@1.31	ME177988	1.21	0.60	0.94
PC 32:3; [M-Ac-H]-@5.07	ME177824	1.12	0.49	1.03
PC 40:3; [M-Ac-H]-@7.43	ME177859	1.08	0.58	1.04
CL 76:6; [M-2H](2-)@6.65	ME177792	1.10	0.62	1.02
PC 37:3; [M-Ac-H]-@7.01	ME177845	1.12	0.58	1.01
PG 38:4; [M-H]-@6.04	ME177947	1.13	0.60	1.00
PE 36:5; [M-H]-@5.82	ME177899	1.41	0.61	0.79
lysoPE 18:3; [M-H]-@1.11	ME177989	1.36	0.68	0.81
PE 38:4; [M-H]-@5.73	ME177912	1.34	0.67	0.83
CL 72:8; [M-2H](2-)@8.91	ME177787	1.30	1.04	0.77
PE 36:3; [M-H]-@5.14	ME177894	1.38	0.96	0.72
PE 33:1; [M-H]-@6.47	ME177872	1.14	0.87	0.93
CL 72:7; [M-2H](2-)@9.11	ME177786	1.13	0.92	0.92
plasmenyl-PE 34:2; [M-H]-@6.60	ME178002	1.12	0.93	0.92
PE 34:1; [M-H]-@5.99	ME177876	1.21	0.97	0.85
PC 33:0; [M-Ac-H]-@6.94	ME177825	1.15	0.96	0.90
PE 33:2; [M-H]-@5.98	ME177873	1.18	0.96	0.88
lysoPE 20:3; [M-H]-@1.58	ME177991	1.21	0.84	0.88
PE 35:2; [M-H]-@6.48	ME177884	1.23	0.82	0.93
lysoPE 17:0; [M-H]-@1.98	ME177985	1.28	0.94	0.80
PE 35:4; [M-H]-@5.98	ME177886	1.25	0.88	0.84
PG 38:2; [M-H]-@5.98	ME177944	1.13	1.20	0.85
PA 39:4; [M-H]-@6.28	ME177812	1.15	1.08	0.87
CerP 33:1; [M-H]-@5.41	ME177801	1.12	1.11	0.89
PE 34:3; [M-H]-@5.83	ME177880	1.13	1.13	0.87
PC 35:3; [M-Ac-H]-@6.11	ME177835	1.08	1.15	0.90
PE 34:1; [M-H]-@5.42	ME177875	1.08	1.08	0.92
PE 32:2; [M-H]-@5.66	ME177871	1.04	0.96	0.98
plasmenyl-PE 34:3; [M-H]-@6.20	ME178003	1.05	0.97	0.97
PC 33:1; [M-Ac-H]-@6.54	ME177826	1.03	0.93	0.99
PC 31:1; [M-Ac-H]-@5.94	ME177819	1.02	0.94	1.00
PE 37:4; [M-H]-@6.57	ME177904	1.02	0.93	1.00
PC 36:2; [M-Ac-H]-@6.78	ME177839	1.00	0.95	1.02
PE 34:2; [M-H]-@6.32	ME177878	1.00	0.93	1.02
PC 36:1; [M-Ac-H]-@7.22	ME177838	0.98	1.06	1.00
PE 32:1; [M-H]-@6.14	ME177870	0.99	1.02	1.00
plasmenyl-PE 36:2; [M-H]-@6.50	ME178008	0.95	0.97	1.04
PA 34:2; [M-H]-@6.17	ME177809	0.97	0.97	1.03
PE 36:2; [M-H]-@6.18	ME177893	0.97	0.98	1.03
CL 70:1; [M-2H](2-)@6.00	ME177782	0.95	1.01	1.04
PC 34:1; [M-Ac-H]-@6.59	ME177829	0.96	1.02	1.02
PC 38:5; [M-Ac-H]-@6.27	ME177853	0.92	1.03	1.05
PE 36:4; [M-H]-@6.13	ME177898	0.91	1.05	1.06
CL 76:3; [M-2H](2-)@6.71	ME177790	0.94	1.14	1.01
PE 30:0; [M-H]-@5.98	ME177868	0.95	1.14	1.01
PE 39:4; [M-H]-@7.01	ME177918	0.94	1.10	1.02
plasmenyl-PE 36:3; [M-H]-@6.78	ME178010	0.93	1.07	1.03
PC 38:3; [M-Ac-H]-@6.98	ME177851	0.92	1.08	1.04
PC 38:7; [M-Ac-H]-@5.39	ME177855	0.92	1.09	1.03
PE 36:2; [M-H]-@6.87	ME177891	0.90	1.10	1.05
PE 40:4; [M-H]-@6.78	ME177923	0.90	1.14	1.04
PG 38:3; [M-H]-@5.77	ME177945	0.90	1.12	1.04
CL 76:8; [M-2H](2-)@9.34	ME177794	0.99	1.11	0.98
PE 40:5; [M-H]-@6.31	ME177924	1.02	1.13	0.96
PE 38:2; [M-H]-@6.78	ME177909	0.98	1.23	0.96
IS PC 34:0;[M-Ac-H]-	ME177804	1.00	1.19	0.95
IS PI 34:0 ;[M-H]-	ME177805	1.03	1.17	0.94
PG 40:7; [M-H]-@5.07	ME177953	0.70	1.07	1.21
PA 36:3; [M-H]-@6.15	ME177810	0.86	1.03	1.10
PC 38:4; [M-Ac-H]-@6.71	ME177852	0.87	1.02	1.09
PI 38:3; [M-H]-@6.13	ME177961	0.85	1.05	1.10
plasmenyl-PE 36:4; [M-H]-@6.53	ME178011	0.83	1.05	1.12
PC 29:0; [M-Ac-H]-@5.45	ME177817	0.78	0.96	1.18
CerP 34:1; [M-H]-@5.76	ME177802	0.79	0.98	1.16
PE 34:0; [M-H]-@6.50	ME177874	0.80	0.98	1.16
PE 34:1; [M-H]-@6.78	ME177877	0.81	1.02	1.14
PE 36:3; [M-H]-@6.47	ME177896	0.77	1.02	1.16
plasmenyl-PE 38:5; [M-H]-@6.65	ME178017	0.77	1.05	1.16
PG 38:6; [M-H]-@4.90	ME177949	0.83	1.28	1.06
plasmenyl-PE 38:4; [M-H]-@7.11	ME178016	0.80	1.33	1.07
PG 35:2; [M-H]-@6.59	ME177935	0.92	1.21	1.01
PC 33:2; [M-Ac-H]-@6.04	ME177827	0.87	1.27	1.03
PE 35:1; [M-H]-@7.02	ME177883	0.88	1.28	1.02
CL 78:3; [M-2H](2-)@6.74	ME177795	0.90	1.28	1.00
PC 40:5; [M-Ac-H]-@6.90	ME177860	0.90	1.25	1.01
plasmenyl-PE 34:1; [M-H]-@7.04	ME178001	0.92	1.25	0.99
lysoPE 18:1; [M-H]-@1.73	ME177987	0.87	1.17	1.05
plasmenyl-PE 34:0; [M-H]-@7.11	ME178000	0.86	1.20	1.06
PE 36:1; [M-H]-@6.60	ME177890	0.81	1.21	1.09
PE 40:5; [M-H]-@6.99	ME177925	0.79	1.13	1.12
CL 76:11; [M-2H](2-)@6.67	ME177788	0.79	1.16	1.12
PC 40:8; [M-Ac-H]-@5.70	ME177863	0.80	1.17	1.11
PC 33:3; [M-Ac-H]-@6.05	ME177828	0.68	1.21	1.19
CL 80:13; [M-2H](2-)@6.01	ME177798	0.77	1.27	1.11
PG 38:5; [M-H]-@5.14	ME177948	0.72	1.24	1.15
PG 42:8; [M-H]-@5.22	ME177954	0.73	1.27	1.13
PC 35:4; [M-Ac-H]-@6.02	ME177836	0.68	0.73	1.31
PE 34:4; [M-H]-@5.64	ME177881	0.70	0.63	1.32
PE 38:5; [M-H]-@5.04	ME177915	0.69	0.89	1.26
PG 36:3; [M-H]-@5.24	ME177940	0.71	0.88	1.25
PA 28:4; [M-H]-@1.77	ME177808	0.65	0.95	1.27
plasmenyl-PE 40:4; [M-H]-@6.63	ME178023	0.66	0.94	1.27
CL 80:12; [M-2H](2-)@7.14	ME177797	0.69	0.93	1.25
PG 40:4; [M-H]-@6.01	ME177950	0.68	0.94	1.26
plasmenyl-PE 40:6; [M-H]-@7.11	ME178025	0.79	0.72	1.23
plasmenyl-PE 38:6; [M-H]-@6.47	ME178018	0.76	0.71	1.25
PS 36:3; [M-H]-@5.51	ME177971	0.77	0.71	1.25
PG 36:2; [M-H]-@5.84	ME177939	0.81	0.86	1.18
PE 40:6; [M-H]-@6.74	ME177926	0.76	0.80	1.23
PS 38:1; [M-H]-@6.96	ME177973	0.76	0.82	1.22
CerP 32:1; [M-H]-@5.03	ME177800	0.78	0.82	1.21
PE 38:6; [M-H]-@6.06	ME177916	0.77	0.84	1.21
PG 34:1; [M-H]-@5.68	ME177932	0.74	0.85	1.23
PI 40:6; [M-H]-@5.79	ME177965	0.73	0.82	1.25
lysoPE 20:4; [M-H]-@1.29	ME177992	0.85	0.60	1.21
PS 34:2; [M-H]-@5.33	ME177968	0.85	0.66	1.20
PC 19:2; [M-Ac-H]-@1.32	ME177816	0.88	0.65	1.18
PS 32:1; [M-H]-@5.14	ME177966	0.88	0.62	1.19
PG 34:3; [M-H]-@4.54	ME177934	1.04	0.62	1.07
plasmenyl-PE 32:1; [M-H]-@6.49	ME177997	1.05	0.54	1.08
PC 30:1; [M-Ac-H]-@5.30	ME177818	1.03	0.57	1.09
PG 38:4; [M-H]-@5.30	ME177946	1.02	0.54	1.10
PC 34:4; [M-Ac-H]-@5.41	ME177832	0.97	0.54	1.14
lysoPE 16:0; [M-H]-@1.61	ME177983	0.97	0.59	1.12
PA 40:7; [M-H]-@6.01	ME177814	0.96	0.57	1.14
CL 82:11; [M-2H](2-)@5.81	ME177799	0.98	0.64	1.11
lysoPE 22:6; [M-H]-@1.23	ME177996	0.94	0.63	1.14
PC 39:5; [M-Ac-H]-@6.72	ME177856	0.92	0.67	1.14
PC 34:2; [M-Ac-H]-@6.15	ME177830	0.98	0.86	1.05
PC 38:6; [M-Ac-H]-@5.91	ME177854	0.92	0.86	1.10
CerP 34:2; [M-H]-@5.23	ME177803	0.94	0.84	1.09
PC 36:3; [M-Ac-H]-@6.31	ME177840	0.94	0.85	1.08
PC 19:1; [M-Ac-H]-@1.72	ME177815	0.92	0.72	1.13
PC 35:1; [M-Ac-H]-@6.98	ME177833	0.96	0.76	1.09
PG 36:0; [M-H]-@6.87	ME177937	0.95	0.74	1.10
PC 37:4; [M-Ac-H]-@6.59	ME177846	0.89	0.81	1.13
PI 38:4; [M-H]-@5.84	ME177962	0.91	0.81	1.12
PG 35:3; [M-H]-@6.17	ME177936	0.92	0.79	1.11
PS 36:4; [M-H]-@5.30	ME177972	0.91	0.77	1.13
PA 40:6; [M-H]-@6.14	ME177813	0.87	0.84	1.14
PE 38:4; [M-H]-@6.86	ME177913	0.87	0.83	1.14
PG 36:4; [M-H]-@4.86	ME177941	0.85	0.77	1.17
PA 26:3; [M-H]-@1.41	ME177807	0.84	0.81	1.16
PC 31:2; [M-Ac-H]-@5.50	ME177820	0.85	0.80	1.16
PC 32:1; [M-Ac-H]-@6.01	ME177822	1.14	0.74	0.96
plasmenyl-PE 33:1; [M-H]-@6.78	ME177999	1.17	0.72	0.94
PE 37:5; [M-H]-@5.98	ME177905	1.04	0.77	1.03
CL 76:5; [M-2H](2-)@6.15	ME177791	1.00	0.80	1.05
PI 38:5; [M-H]-@5.35	ME177963	1.02	0.80	1.04
PG 40:5; [M-H]-@5.65	ME177951	1.06	0.79	1.01
PA 36:4; [M-H]-@6.12	ME177811	1.05	0.81	1.01
PC 35:2; [M-Ac-H]-@6.52	ME177834	1.06	0.82	1.00
plasmenyl-PE 36:5; [M-H]-@6.16	ME178012	1.04	0.86	1.00
PC 36:4; [M-Ac-H]-@6.02	ME177841	1.02	0.83	1.03
PC 39:6; [M-Ac-H]-@6.43	ME177857	1.02	0.84	1.02
PE 38:3; [M-H]-@6.31	ME177911	1.06	0.69	1.03
PC 32:2; [M-Ac-H]-@5.50	ME177823	1.09	0.68	1.01
PC 34:3; [M-Ac-H]-@5.65	ME177831	1.08	0.71	1.01
PE 40:6; [M-H]-@5.82	ME177927	1.00	0.69	1.08
lysoPE 18:0; [M-H]-@2.39	ME177986	1.03	0.71	1.05
PC 40:7; [M-Ac-H]-@6.01	ME177862	1.03	0.74	1.04

Factors:

F1	Genotype:HSL heterozygote
F2	Genotype:HSL KO
F3	Genotype:WT

Data matrix